Paris Abstracts months pre-and post-index periods. Patients with diabetic peripheral neuropathic pain (DPNP) or depression in the 12 months pre-index period were excluded. Each patient was classified in the duloxetine or prebagalin cohort based on the initial agent. Prebagalin cohort was constructed via propensity scoring controlling for differences in demographics, pre-index clinical and economic characteristics, and pre-index treatment patterns. Medication compliance (i.e. medication possession ratio (MPR) and proportion of patients with MPR 80%) and health care costs over the 12 months post-index period were examined between cohorts. RESULTS: Both the duloxetine (n 3711) and pregabalin (n 4111) cohorts had the mean age around 50 years. Many duloxetine and pregabalin patients had neuropathic pain other than DPNP (69.1% vs. 69.1%), low back pain (61.9% vs. 62.1%), cardiovascular disease (55.1% vs. 55.1%), hypertension (44.9% vs. 45.0%), and headache (36.0% vs. 35.3%), and used opioids (75% vs. 86%). Controlling for demographics, pre-index clinical and economic characteristics, and prior medication history, duloxetine patients had significantly higher MPR (0.66 vs. 0.50, p 0.05), higher proportion of patients with MPR 80% (47% vs. 26%, p 0.05), and significantly lower total health care costs ($19,378 vs. $27,045, p 0.05) over the 12 months follow-up period than pregabalin patients. CONCLUSIONS: Fibromyalgia patients treated with duloxetine had significantly higher medication compliance, but significantly lower direct health care costs than those on pregabalin.
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IMS Health GmbH & Co. OHG, Munich, Germany, 2 Amgen GmbH Germany, Munich, Germany, 3 IMS Health GmbH & Co. OHG, Frankfurt am Main, Germany, 4 Amgen Europe GmbH, Zug, Switzerland OBJECTIVES: To describe the adherence for different treatment regimens of oral bisphosphonates (oBP) in osteoporosis patients in Germany. METHODS: Analyses used IMS® Disease Analyser database (contains representative information on approximately 11 million patients from office-based physicians). Osteoporosis patients with a history of malignant diseases, any anticancer or cytostatic hormone prescriptions, Paget's disease or AIDS were excluded. Eligible osteoporosis patients had data available at least 1-year before and after starting oBP treatment between Dec 2004 and Nov 2007 . Compliance was measured as Medical Possession Ratio (MPR); defined as the ratio of prescribed to assumed number of therapy units. MPR 80% assumed compliance. MPR was calculated for patients on therapy for a maximum of 2 years. RESULTS: Data from 4,738 patients were analyzed: 4147 (87.5%) women, 4130 (87.2%) older than 60 years. A total of 177 (3.7%) received daily, 4367 (92.2%) weekly and 194 (4.1%) monthly oBP treatment. The mean MPR was 0.66 (daily), 0.83 (weekly) and 0.84 (monthly) in the oBP treatment period. In total, only 51% of patients had an MPR 80%. Overall, 72% patients discontinued/switched oBP regimen during the first year: 90.4% (daily), 71.6% (weekly) and 70.6% (monthly). CONCLUSIONS: The majority of patients were receiving weekly oBP therapy. Compliance varied for the different treatment regimens, but was particularly poor in patients receiving daily oBP treatment. In addition, a high proportion of patients discontinued/switched oBP regimens during the first year. This study provides further evidence of poor adherence in patients with osteoporosis receiving oBP therapy. To reduce and validate the ADEOS questionnaire, an instrument specifically developed to evaluate treatment adherence by women with post-menopausal osteoporosis. METHODS: The ADEOS questionnaire has been developed with clinicians and patients. Before item reduction, it included 45 items covering 5 distinct themes related to adherence (personal characteristics, beliefs, perceptions, behaviour and information received). It was included for finalisation and validation in a crosssectional observational study in French general practitioners. The study sample was randomly divided into 2 subsamples: one for item selection, one for validation. The item selection procedure was performed according to the association of the items with a generic measure of compliance, the Morisky Medication Adherence Scale (MMAS). The validity of the score derived from these items was scrutinised by assessing its correlation with MMAS score. Its ability to separate compliant patients from non compliant patients according to MMAS was studied using area under receiver-operating characteristic curve (AUC). RESULTS: Five hundred sixty osteoporotic women were included, of whom 348 (62%) returned the ADEOS questionnaire. Patients who did not return the questionnaire were comparable to those who did in terms of demographics and medical parameters. The questionnaire quality of completion was very good, confirming its good acceptability. Twelve items of the questionnaire showed a statistically significant relationship (p 0.05) with the MMAS in the "item selection sample" (N 200) and were retained to derive the ADEOS score. In the "validation sample" (N 148), the ADEOS score was noticeably correlated with MMAS score (Spearman correlation coefficient: 0.58) and showed good discriminant validity according to MMAS (AUC: 0.84). CONCLUSIONS: The 12-item ADEOS questionnaire is a short validated instrument specific to osteoporosis, whose score can easily be calculated by hand. Therefore, it might be particularly useful in daily practice to detect patients at risk of being poorly adherent to their osteoporosis treatment.
PMS69 ITEM REDUCTION AND VALIDATION OF A NEW ADHERENCE QUESTIONNAIRE IN OSTEOPOROTIC POST-MENOPAUSAL WOMEN: THE ADHERENCE EVALUATION OF OSTEOPOROSIS TREATMENT (ADEOS) QUESTIONNAIRE

PMS70
USE OF QUALITATIVE RESEARCH TO ELICIT PATIENT-REPORTED OUTCOME APPROACHES IN OSTEOPOROSIS
Alegre P 1 , Marant C 2 , Vigneux M 2 , Seignobos E 2 1 Servier, Suresnes, France, 2 Mapi Values, Lyon, France OBJECTIVES: Recent anti-osteoporotic treatments are characterised by monthly or even yearly administration. These treatments may challenge the prescription of dailyadministered drugs. The objective of this qualitative research was to explore patients' perception as well as clinicians' views on the frequency of anti-osteoporotic treatment administration. METHODS: A health psychologist carried out face-to-face interviews with six patients treated on a daily basis and six patients treated with a monthlyadministered drug. The patients' perception, behaviour and expectations regarding anti-osteoporotic treatment were assessed. Clinicians who recruited the patients, comprising a general practitioner and specialists, were also interviewed. Information on factors driving their treatment choice decision and on the importance of patients' feedback and perception in their decision was collected. RESULTS: Patients perceived osteoporosis as a sign of premature ageing and a disease of secondary importance. They reported that a daily administration was not a problem per se if it did not modify their lifestyle. They raised concerns about lower frequency of drug administration that clinicians did not: the difficulty of remembering to take the treatment; the worry about the treatment being too concentrated, with the thought of a possible irregular efficacy of the drug over the time and a harmful effect. They did not feel involved in the choice of treatment. Clinicians believed monthly administration to be more convenient than daily administration. They declared choosing the treatment according to the patient's characteristics, in particular concomitant diseases, lifestyle, and dosing preference. CONCLUSIONS: Discrepancies exist between clinicians' perception and reality for patients regarding anti-osteoporotic treatment. Consequently, possible patientreported outcomes approaches to improve treatment-decision would consist in 1) educating patients on osteoporosis, and clinicians on their patients' perception and expectations, and 2) promoting shared decision-making. This is likely to contribute to a better persistence of the patients with regard to their treatment.
PMS71 PREDICTING CHANGES IN EQ-5D UTILITY SCORE VIA PASI OR HAQ IN PSORIATIC ARTHRITIS PATIENTS
Zbrozek A 1 , Kirkham B 2 , Li W 1 , Molta C 1 , Singh A 1 1 Wyeth Research, Philadelphia, PA, USA, 2 University of New South Wales, Sydney, NSW, Australia OBJECTIVES: To compare the predictive power post hoc of skin signs and physical function in improvement of health state utility scores in a population with active psoriatic arthritis (PsA). METHODS: A 12-week randomized double-blind study followed by a 12-week open-label extension; subjects received etanercept 50 mg BIW or 50 mg QW during the double-blind period followed by 50 mg QW during the openlabel period. Eligibility criteria included: age 18 y; stable, moderate-to-severe plaque psoriasis with 2 swollen/painful joints. PASI for psoriasis signs, HAQ for physical function, and EQ-5D were measured at baseline, Weeks 12 and 24. Logistic regression was used to predict the minimally clinically meaningful change in EQ-5D of at least 0.05 (0-1.0 scale). Meaningful changes from baseline as predictors: HAQ 0.375, 0.5; PASI 50%, 75%. RESULTS: At baseline, subjects (n 752) had a mean age 47 y, were 63% male, and 89% white. Mean number of tender joints 19.2, and swollen joints 12.5. Mean durations of psoriasis and psoriatic arthritis 19 and 7 years, respectively. Baseline scores were not significantly different between the 2 groups; pooled baseline (mean s.d.) PASI 19.43 10.28, HAQ 0.91 0.69, and EQ-5D 0.48 0.32. Only PASI change from baseline at Week 12 differentiated treatment groups. Pooled reductions from baseline to Week 24 (LOCF) were: PASI 75.9%, HAQ 52.0%. Proportion achieving EQ-5D ( 0.05) 74.6%. HAQ changes from baseline were stronger predictors of pre-determined changes in EQ-5D utility scores than PASI changes, with HAQ change 0.375 at Week 24 being the strongest single change predictor (OR 4.36 (2.01-9.44)). Higher baseline HAQ scores reduced the odds 0.12 (0.07-0.20), and 0.19 (0.11-0.31) for minimally meaningful health status improvements at Weeks 12 and 24, respectively. CONCLUSIONS: Patients with less advanced PsA could have better odds of meaningful improvement in health status when treated to reduce both skin and joint morbidity.
PMS72 A CALIBRATION OF THE RELATIONSHIP BETWEEN THE HAQ, THE SF-6D AND THE EQ-5D IN INFLAMMATORY ARTHRITIS
Adams R 1 , Walsh C 2 , Tilson L 1 , FitzGerald O 3 , Bresnihan B 3 , Veale D 3 , Barry M 1 1 National Centre for Pharmacoeconomics, Dublin, Ireland, 2 Trinity College Dublin, Dublin, Ireland, 3 St Vincents University Hospital, Dublin, Ireland OBJECTIVES: To examine the relationship between disease specific-measure, Health Assessment Questionnaire (HAQ) disability index (DI) and the preference-based measures, Short Form-6D (SF-6D) and the EuroQoL (EQ-5D) in patients with rheumatoid arthritis(RA) and psoriatic arthritis (PsA). METHODS: Five hundred and four patients attending a rheumatology outpatient clinic with RA and PsA completed the HAQ, Short Form-36 and the EQ-5D before starting biologic therapy and 12 months after.
The SF-36 was converted into a utility using the preference-based SF-6D. Clinical outcomes such European League Against Arthritis (EULAR) Disease Activity Score (DAS), joint counts and laboratory measures were also recorded. We calculated single index utility scores from the preference-based instruments using UK population norms. We used regression analysis and correlation coefficients to compare relationships between the Quality of Life (QoL) outcomes and also the clinical outcomes and between observed and mapped utility scores. RESULTS: There was a significant difference between the mapped and observed EQ-5D and SF-6D. Overall the mapped utilities produced higher values than the actual observed scores. The mean change in utility due to treatment is greater with the EQ-5D for both mapped and observed utilities. A greater change was seen in the PsA group. CONCLUSIONS: We present the different results produced when using mapped utility scores and directly obtained scores. We have highlighted the problems associated with deriving utilities from non preference-based instruments and the differences in utilities when calculated using different measures. While these methods do offer alternatives for researchers when performing cost utility analysis they remain suboptimal to the direct method.
PMS73 CONTENT VALIDITY OF THE FIBROMYALGIA SYNDROME BURDEN ASSESSMENT (FMBA©)
Serra E 1 , Spaeth M 2 , Carbonell JA 3 , Arnould B 4 , Benmedjahed K 5 , Barnes N 4 , Le Lay K 6 , Taieb C 6 1 Amiens University Hospital, Amiens, France, 2 Clinical Center for Rheumatology, Graefelfing/ Muenchen, Germany, 3 Hospital de la Esperanz, Barcelona, Spain, 4 Mapi Values, Lyon, France, 5 Mapi Values France, Lyon, France, 6 PFSA, Boulogne, France OBJECTIVES: To test the comprehension of the FMBA © in France, Germany and Spain. METHODS: The FMBA © was tested to assess ease of comprehension, cultural equivalence, clarity, wording and acceptability of the structure and content to patients. The test version contained 79 items grouped into 7 sections measuring burden of fibromyalgia on patients' daily lives, developed simultaneously in French, German, Spanish and UK English. These sections evaluate Pain, Physical Impact, Impact on daily activities, Social Impact, Work Impact, Psychological Impact, Relationship to doctors and treatment, and One general item. Sixteen fibromyalgia patients were interviewed in France, Germany and Spain. UK comprehension tests are currently under way. Based on test results and deliberation with fibromyalgia experts, changes were made to the French, German, Spanish and UK English versions of the questionnaire during an international harmonisation meeting. RESULTS: Patients' overall comprehension of the questionnaire was good. The comprehension tests identified problematic items, and suggestions for deletions or rewording. Seventeen items were deleted for reasons such as; lack of conceptual clarity e.g. "I have pain that changes from one moment to the next" not clear between location and intensity; items considered conceptually too close e.g. "I get tired for no reason" deleted because too close to "I lack energy" and "I get tired easily"; and wording too strong" e.g. "I feel handicapped". The answer choices were also modified to ensure cultural acceptance. The pilot version of the FMBA © contains 62 items divided into 7 sections. CONCLU-SIONS: The FMBA © is a questionnaire that assesses the functional impact and burden of fibromyalgia on patients' daily lives. The FMBA © will allow the consequences of FM on patients to be more widely recognised. A validation study is to be undertaken to validate psychometric properties and scoring of the questionnaire.
PMS74
DEVELOPMENT OF A TOOL TO HELP IN THE EARLY DETECTION OF FIBROMYALGIA (FM) IN GENERAL PRACTICE IN EUROPE
Dias-Barbosa C 1 , Guillemin I 1 , Perrot S 2 , Baron R 3 , Alegre C 4 , Choy E 5 , Cruccu G 6 , Desmeules J 7 , Margaux J 8 , Richards S 9 , Serra E 10 , Spaeth M 11 , Arnould B 1 1 Mapi Values, Lyon, France, 2 Hôpital Hôtel Dieu Paris, Paris, France, 3 Christian-Albrechts Universit, Kiel, Germany, 4 Hospital General Universtiari, Barcelona, Spain, 5 King's College, London, UK, 6 La Sapienza University, Roma, Italy, 7 Geneva University Hospital, Geneva, Switzerland, 8 Erasme Hospital, Brussels, Belgium, 9 Poole Hospital NHS Trust, Poole, UK, 10 North Hospital, Amiens, France, 11 Rheumatology, Gräfelfing, Germany OBJECTIVES: To develop a European screening tool to help primary care physicians (PCPs) identify fibromyalgia (FM) patients in general practice. METHODS: A European multidisciplinary expert group was set up to provide clinical expertise and identify key issues around FM detection. A literature review and focus groups conducted with French (FR), German (DE) and English (UK) clinicians provided an overview of the knowledge in FM and of clinicians' awareness and experience. Psychologists then performed face-to-face exploratory interviews with FM patients (FR, DE and UK, n 29) to understand their attitudes and perceptions of the disease. Based on the findings, items were simultaneously generated in FR, UK and DE. The resulting tool was comprehension tested with FM-diagnosed or -suspected patients (n 3 and n 2 in each country, respectively), and modified based on results. Its acceptability and applicability was then assessed in real-life conditions in general practice. RESULTS: The tool content defined using literature review, health professional and patient input had high consistency regardless of the source from which it was extracted. Factors found that may contribute to the early detection of FM included elements of FM definition, patient characteristics, personal and medical history, quality of life, attitude and personality, associated symptoms and influencing factors. The resulting pilot version of the FM screening tool includes 14 questions assessing patients' pain, fatigue, associated symptoms, impact on patients' everyday life, personal history, and attitudes towards their symptoms. Face validity and feasibility have been confirmed by PCPs and patients when administered in general practice. CONCLUSIONS: In addition to the symptomatic picture, FM detection requires the assessment of multiple factors including patient past history and characteristics, impact of FM on patients' daily life, and situations/factors affecting patients' condition. By capturing each of these factors, the European FM screening tool will help PCPs identify potential FM patients. Quantitative validation of the tool is underway.
PMS75 OAKHQOL, A DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE FOR OSTEOARTHRITIS OF THE LOWER LIMB. VALIDITY AND RESPONSIVENESS
Escobar A 1 , González M 1 , Sarasqueta C 2 , Aizpuru F 3 , Herrera C 4 , García-Pérez L 5 1 Hospital de Basurto, Bilbao, Spain, 2 Hospital Donostia, Donostia-San Sebastian, Spain, 3 Hospital de Txagorritxu, Vitoria-Gasteiz, Spain, 4 Hospital Virgen de las Nieves, Granada, Spain, 5 Fundación Canaria de Investigación y Salud, Santa Cruz de Tenerife, Spain OBJECTIVES: Health related quality of life (HRQoL) is an important issue to evaluate outcomes after health interventions. The aim of this study was to study construct validity and responsiveness of the OsteoArthritis of Hip and Knee Quality of Life questionnaire (OAKHQOL), a disease-specific HRQoL for osteoarthritis of the lower limb. METHODS: OAKHQOL is a self administered questionnaire and has 43 items and five dimensions: physical activities (16), pain (4), mental health (13), social support (4) and social functioning (3). There are 3 independent items about relationships, sexual activities and professional life. The score range from 0 (worst) to 100 (best health). Patients were recruited patients from the waiting list to undergo joint replacement. The internal consistency was measured by Cronbach´s alpha (771 patients). The test-retest reliability (413 stable patients who fulfilled the questionnaire two times) was measured by Intraclass correlation coefficient (ICC). The responsiveness was evaluated by means of standardized effect size (SES) and standardized response mean (SRM) six months post surgical replacement. RESULTS: Cronbach´s alpha were all higher than 0.8 but in social activities dimension (0.64). Regarding test-retest reliability the ICCs were higher than 0.75 but in the social activities (0.4) and social support (0.4) dimensions. Finally, responsiveness parameters were: physical dimension (SES 1.26; SRM 0.89); pain (SES 1.37; SRM 0.94); mental health (SES 0.65; SRM 0.56). CONCLUSIONS: These results support the validity and responsiveness of the Spanish version of the OAKHQOL a disease specific HRQoL questionnaire to be used in patients with osteoarthritis of the lower limb and surgical management.
PMS76 PATIENT REPORTED QUALITY-OF-LIFE ISSUES IN MYOTONIC DYSTROPHY TYPE-1 (DM1): A FIRST STEP IN THE DEVELOPMENT OF A DISEASE-SPECIFIC INSTRUMENT
Heatwole C 1 , Chin N 1 , Hilbert J 1 , Holloway R 1 , Johnson N 1 , Pandya S 1 , Moxley R 1 , Quinn C 1 , Thornton C 1 , Vickrey B 2 , Victorson DE 3 1 The University of Rochester Medical Center, Rochester, NY, USA, 2 The Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA, 3 Northwestern University Feinberg School of Medicine/Evanston Northwestern Healthcare, Evanston, IL, USA OBJECTIVES: Development of validated patient-reported outcome (PRO) measures has the potential to positively impact scientific research and patient management. To date, the specific issues and symptoms most relevant to DM1 patients' health related quality-of-life (HRQOL) have not been systematically assessed. Our goal is to identify those aspects of HRQOL that are most important to patients with DM1, a neuromuscular condition with multisystemic organ dysfunction. METHODS: We conducted in-depth individual patient interviews with twenty genetically confirmed, adult, DM1 patients representing varied levels of disability. Each interview focused on identifying the DM1 issues that have the greatest impact on patient HRQOL. Each interview was recorded, transcribed, coded, and analyzed using a qualitative framework technique, triangulation, and three investigator consensus approach. RESULTS: A total of 1175 direct quotes were coded resulting in 223 like themes. These themes were subsequently categorized into 7 subdomains representing physical, mental, and social aspects of DM1 HRQOL. A disease-specific HRQOL conceptual model was created for DM1 representing the most relevant symptomatic and psychosocial issues in this population. Categories in this model included: 1) mobility and ambulation/ fine motor and upper extremity dysfunction; 2) emotional distress; 3) cognitive impairment; 4) social role limitations; 5) social role dissatisfaction; 6) activity impairment; and, 7) DM1-specific symptoms of: sleep disturbance, fatigue, pain/myotonia, gastrointestinal dysfunction, central sensory impairment, and communication difficulties. Difficulty with ambulation was the most frequently mentioned issue by our sample of patients. CONCLU-SIONS: There are multiple themes and symptoms, some previously underrecognized, that play a key role in DM1 patient reported HRQOL. These issues must be carefully examined in order to develop a representative disease-specific conceptual model and PRO measurement tool. The development of such an instrument has the potential to improve DM1 clinical care and maximize the impact and relevance of future DM1 clinical research.
PMS77 FURTHER DEVELOPMENTS OF THE RHEUMATOID ARTHRITIS QUALITY OF LIFE SCALE (RAQOL)
Wilburn J, McKenna SP, Twiss J Galen Research Ltd, Manchester, UK OBJECTIVES: The Rheumatoid Arthritis Quality of Life scale (RAQoL) is the first true QoL measure for RA and is widely used in clinical practice and trials. The scale has good psychometric properties and has been shown to be responsive to changes in disease severity. The objective of the study was to adapt the RAQoL for USA, Mexico,
